8-K: Johnson & Johnson Reports Strong Q2 2025 Results, Raises Full-Year Outlook

Johnson & Johnson announced robust second-quarter 2025 financial results, with reported sales up 5.8% to $23.7 billion and adjusted EPS of $2.77, leading to an increased full-year guidance.

Summary

• Reported sales for the second quarter of 2025 increased by 5.8% to $23.743 billion, with operational growth of 4.6% and adjusted operational growth of 3.0%.
• Net earnings for Q2 2025 were $5.537 billion, an 18.2% increase compared to $4.686 billion in Q2 2024.
• Diluted earnings per share (EPS) for Q2 2025 were $2.29, up 18.7% from $1.93 in Q2 2024.
• Adjusted net earnings for Q2 2025 were $6.699 billion, a 2.1% decrease from $6.840 billion in Q2 2024.
• Adjusted diluted EPS for Q2 2025 was $2.77, a 1.8% decrease from $2.82 in Q2 2024.
• Estimated free cash flow for the second quarter year-to-date 2025 was approximately $6.2 billion, down from $7.507 billion in the prior year period.
• Innovative Medicine worldwide operational sales grew 3.8% to $15.202 billion, driven by DARZALEX, CARVYKTI, ERLEADA, RYBREVANT/LAZCLUZE in Oncology, TREMFYA and SIMPONI/SIMPONI ARIA in Immunology, and SPRAVATO in Neuroscience.
• Innovative Medicine growth was partially offset by an approximate 1,170 basis points impact from STELARA and 130 basis points impact from COVID-19.
• MedTech worldwide operational sales grew 6.1% to $8.541 billion, primarily driven by electrophysiology products and Abiomed in Cardiovascular, as well as wound closure products in General Surgery.
• Full-year 2025 estimated reported sales guidance was raised to a midpoint of $93.4 billion (from $91.4 billion), representing 5.4% growth.
• Full-year 2025 adjusted EPS guidance was raised to a midpoint of $10.85 (from $10.60), representing 8.7% growth.

Sentiment

Score: 8

Explanation: The company reported strong Q2 results, significantly raised its full-year sales and EPS guidance, and highlighted substantial pipeline progress and new product approvals, indicating robust operational performance and a positive outlook despite some product-specific declines.

Positives

• Strong Q2 2025 reported sales growth of 5.8% to $23.743 billion.
• Net earnings increased significantly by 18.2% to $5.537 billion in Q2 2025.
• Reported diluted EPS rose by 18.7% to $2.29 in Q2 2025.
• Full-year 2025 estimated reported sales guidance was raised by $2 billion at the midpoint to $93.4 billion.
• Full-year 2025 adjusted EPS guidance was raised by $0.25 at the midpoint to $10.85.
• Innovative Medicine segment achieved 3.8% operational sales growth, with strong performance from key oncology products like DARZALEX (up 21.5% operational) and CARVYKTI (significant growth from $186 million to $439 million worldwide).
• MedTech segment delivered robust 6.1% operational sales growth, driven by electrophysiology products and Abiomed (Cardiovascular, up 22.3% operational worldwide).
• Received FDA approval for IMAAVY (nipocalimab-aahu) for generalized myasthenia gravis, offering long-lasting disease control.
• Achieved priority review for TAR-200, a monotherapy for bladder cancer, demonstrating high disease-free survival and complete response rates.
• Positive clinical data for CARVYKTI showing lasting treatment-free remissions for at least five years in relapsed/refractory multiple myeloma patients.
• Completed first cases with the OTTAVA Robotic Surgical System, indicating progress in general surgery robotics.
• Launched several new products including ACUVUE OASYS MAX 1-Day MULTIFOCAL for ASTIGMATISM, VOLT Wrist and Proximal Humerus Plating Systems, TECNIS Odyssey Next-Generation Intraocular Lens, KINCISE 2 System, and SOUNDSTAR CRYSTAL.

Negatives

• Adjusted net earnings decreased by 2.1% to $6.699 billion in Q2 2025.
• Adjusted diluted EPS decreased by 1.8% to $2.77 in Q2 2025.
• Estimated free cash flow for Q2 YTD 2025 was approximately $6.2 billion, a decrease from $7.507 billion in Q2 YTD 2024.
• STELARA sales significantly declined, impacting Innovative Medicine growth by approximately 1,170 basis points due to patent expiration and competition.
• Sales of COVID-19 vaccine impacted Innovative Medicine growth by approximately 130 basis points.
• IMBRUVICA sales decreased by 6.6% operationally worldwide in Q2 2025.
• ZYTIGA/abiraterone acetate sales decreased by 14.9% operationally worldwide in Q2 2025.
• INVEGA SUSTENNA/XEPLION/INVEGATRINZA/TREVICTA sales decreased by 6.3% operationally worldwide in Q2 2025.
• Orthopaedics segment experienced a slight operational sales decline of 1.6% worldwide in Q2 2025.

Risks

• Economic factors, such as interest rate and currency exchange rate fluctuations or changes to applicable laws and regulations.
• Competition, including technological advances, new products and patents attained by competitors.
• Challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals.
• Uncertainty of commercial success for new and existing products.
• Challenges to patents; the impact of patent expirations.
• The ability of the Company to successfully execute strategic plans, including restructuring plans.
• The impact of business combinations and divestitures.
• Manufacturing difficulties or delays, internally or within the supply chain.
• Product efficacy or safety concerns resulting in product recalls or regulatory action.
• Significant adverse litigation or government action, including related to product liability claims.
• Changes to applicable laws and regulations, including tax laws and global health care reforms.
• Trends toward health care cost containment.
• Changes in behavior and spending patterns of purchasers of health care products and services.
• Financial instability of international economies and legal systems and sovereign risk.
• Increased scrutiny of the health care industry by government agencies.

Future Outlook

Johnson & Johnson increased its full-year 2025 estimated reported sales guidance to a midpoint of $93.4 billion and its adjusted EPS guidance to a midpoint of $10.85, reflecting strong operational performance and favorable foreign exchange. The company anticipates elevated growth in the second half of the year, driven by game-changing approvals and submissions in areas such as lung and bladder cancer, major depressive disorder, psoriasis, surgery, and cardiovascular, which are expected to extend and improve lives in transformative ways.

Management Comments

• "Today's strong results reflect the depth and strength of Johnson & Johnson's uniquely diversified business operating across both MedTech and Innovative Medicine."
• "Our portfolio and pipeline position us for elevated growth in the second half of the year, with game-changing approvals and submissions anticipated in areas like lung and bladder cancer, major depressive disorder, psoriasis, surgery and cardiovascular, which will extend and improve lives in transformative ways."

Industry Context

Johnson & Johnson's strong second-quarter performance, particularly in its Innovative Medicine and MedTech segments, demonstrates its resilience and strategic positioning within the healthcare industry. The company's ability to raise its full-year guidance, despite challenges like the patent expiration of STELARA, highlights the strength of its diversified portfolio and robust pipeline. The focus on new product approvals and submissions in high-growth therapeutic areas such as oncology, immunology, and advanced medical technologies aligns with broader industry trends emphasizing innovation, addressing unmet medical needs, and leveraging technological advancements in surgical systems. This strategic approach positions Johnson & Johnson to maintain its leadership and adapt to evolving market dynamics.

Comparison to Industry Standards

• The document does not provide specific comparable companies, projects, or results for direct assessment against global benchmarks or industry standards.

Management Changes

Legal Proceedings

• Pre-tax adjustment for litigation-related costs of $57 million for the second quarter of 2025.
• Pre-tax adjustment for litigation-related gains of $6,909 million for the six months ended 2025.
• Risk of significant adverse litigation or government action, including related to product liability claims, as a general forward-looking risk.

Stakeholder Impact

• Shareholders/Investors: Positive impact due to strong financial performance, raised guidance, and pipeline progress, potentially leading to increased share value.
• Patients: Positive impact from new product approvals (e.g., IMAAVY) and anticipated 'game-changing' therapies in development, which are expected to extend and improve lives.
• Employees: Potential positive impact from company growth and strategic focus, though restructuring programs in Orthopaedics and Surgery may involve some workforce adjustments.
• Customers (Healthcare Providers): Benefit from new and improved medical technologies and pharmaceutical products, enhancing treatment options and patient care.

Next Steps

• A conference call with investors will be held on July 16, 2025, at 8:30 a.m. Eastern Time to discuss the earnings release.
• Anticipated game-changing approvals and submissions in areas like lung and bladder cancer, major depressive disorder, psoriasis, surgery, and cardiovascular are expected in the second half of 2025.

Key Dates

Recommendation

Keywords

Johnson & Johnson, JNJ, Q2 2025, earnings, sales, financial results, pharmaceutical, MedTech, Innovative Medicine, medical devices, oncology, immunology, neuroscience, cardiovascular, pulmonary hypertension, infectious diseases, FDA approval, pipeline, guidance, EPS, revenue, CARVYKTI, DARZALEX, TREMFYA, STELARA, IMAAVY, OTTAVA